In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Make It Better And Put More Money In – Industry On England’s New Innovative Medicines Fund

While they await further details on England’s new Innovative Medicines Fund, industry and other stakeholders are asking questions about how far the fund – due for launch later this year – will be adapted to fit non-cancer therapies.

Reimbursement United Kingdom

UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date

Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.

United Kingdom Market Access

Could Reformed HTA Be A Legacy Of COVID-19?

The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?

Coronavirus COVID-19 Health Technology Assessment

Where Now For Italy’s Drug Price Transparency Crusade?

The signs suggest that Nicola Magrini, the new director general of the Italian medicines regulator, AIFA, will follow in the footsteps of his predecessor in fighting for transparency in drug pricing.

Italy Appointments

The Tensions In Pursuing Drug Price Transparency In Belgium

In Belgium, there are increasing tensions between drug price transparency and getting the best deal for the Belgian government.

Europe Belgium

Exploring Price Transparency Actions In Europe

Drug pricing is an issue that is not going to go away. For many the problem relates to prices being too high, for others it is simply that the real prices paid for products is not clear, nor is it transparent how those prices come about. 

Market Access Pricing Debate
See All
UsernamePublicRestriction

Register